Prothena Presents Positive Clinical Data on Parkinson's and Alzheimer's Treatments at AD/PD 2026
ByAinvest
Saturday, Mar 21, 2026 4:07 pm ET1min read
PRTA--
Prothena Corporation presented data on its investigational therapeutics for Parkinson's disease and Alzheimer's disease at the AD/PD 2026 conference. Roche presented data on prasinezumab for Parkinson's disease, including sustained effects on motor progression and biomarkers. Prothena also presented data on BMS-986446 for Alzheimer's disease, highlighting its potential as a treatment. The presentations suggest that both prasinezumab and BMS-986446 may have disease-modifying effects, slowing the progression of the diseases.

Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue

Comments
No comments yet